利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.024 秒)

    Therapeutic vaccination method, mutated peptides of hiv reverse transciptase and their use for vaccination and diagnostic purposes
    3.
    发明申请
    Therapeutic vaccination method, mutated peptides of hiv reverse transciptase and their use for vaccination and diagnostic purposes 审中-公开
    治疗性接种方法，hiv逆转录酶的突变肽及其用于疫苗接种和诊断目的

    公开(公告)号：US20050074463A1

    公开(公告)日：2005-04-07

    申请号：US10489123

    申请日：2001-09-14

    申请人： Brigitte Autran ,  Assia Samri ,  Patrice Debre ,  Vincent Calvez ,  Christine Katlama ,  Gaby Haas

    发明人： Brigitte Autran ,  Assia Samri ,  Patrice Debre ,  Vincent Calvez ,  Christine Katlama ,  Gaby Haas

    IPC分类号： A61K38/00 ,  A61K39/00 ,  A61K39/39 ,  A61K48/00 ,  A61P31/00 ,  A61P31/18 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  C12N9/12 ,  C12Q1/02 ,  A61K39/21

    CPC分类号： C12N9/1276 ,  A61K39/00 ,  C12N2799/021

    摘要： The invention concerns treatment of infectious and tumoral pathologies comprising a anti-infective and/or anti-tumoral chemotherapeutic treatment phase inducing resistance mutations and a therapeutic vaccination phase directed against said resistance mutations and the agents used in said treatment More particularly, the invention concerns peptides of 8 to 80 amino acids of the HIV reverse transcriptase sequence and comprising at least a mutation with respect to said wild sequence of said enzyme, mutation induced in response to treatments by nucleoside and non-nucleoside analogues of the HIV reverse transcriptase. The invention also concerns a pharmaceutical composition or vaccine based on said peptides, for inducing an immune response specific of said mutated sequences and for enhancing or prolonging the efficiency of treatments with nucleoside or non-nucleoside analogues of the HIV reverse transcriptase. The invention further concerns epitopes derived from said peptide sequences to evaluate the specific immune response following the vaccine injection.

    摘要翻译： 本发明涉及感染性和肿瘤病理学的治疗，其包括诱导抗性突变的抗感染和/或抗肿瘤化学治疗期，以及针对所述抗性突变的治疗性接种期和用于所述治疗的药剂。更具体地，本发明涉及肽 所述HIV逆转录酶序列的8至80个氨基酸，并且对于所述酶的所述野生型序列至少包含突变，所述突变响应于HIV逆转录酶的核苷和非核苷类似物的处理而诱导。 本发明还涉及基于所述肽的药物组合物或疫苗，用于诱导所述突变序列特异性的免疫应答，并且用于增强或延长用HIV逆转录酶的核苷或非核苷类似物处理的效率。 本发明还涉及来自所述肽序列的表位，以评估疫苗注射后的特异性免疫应答。

    Method of Prognosis and/or Diagnosing an IRS in a Patient Infected with M. Tuberculosis and Optionally HIV
    4.
    发明申请
    Method of Prognosis and/or Diagnosing an IRS in a Patient Infected with M. Tuberculosis and Optionally HIV 审中-公开
    感染结核分枝杆菌和任选的HIV的患者的预后和/或诊断IRS的方法

    公开(公告)号：US20110311992A1

    公开(公告)日：2011-12-22

    申请号：US13148162

    申请日：2010-02-05

    申请人： Brigitte Autran

    发明人： Brigitte Autran

    IPC分类号： G01N33/566

    CPC分类号： G01N33/5695

    摘要： The invention relates to a method of prognosing and/or diagnosing a M. tuberculosis-Immune restoration syndrome (TB-IRS) in an individual infected with M. tuberculosis and optionally HIV comprising comparing the percentage or concentration of γδ+ or γδ+Vδ2+T-lymphocytes which express an inhibitory KIR receptor with a predetermined value.

    摘要翻译： 本发明涉及在感染结核分枝杆菌和任选的HIV的个体中预测和/或诊断结核分枝杆菌 - 免疫恢复综合征（TB-IRS）的方法，包括比较γδ+或γδ+Vδ2+ 表达具有预定值的抑制性KIR受体的T淋巴细胞。